Johnson & Johnson Overview
Latest ROE for Johnson & Johnson: 24.76% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow24.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for JNJ is 24.76%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside Johnson & Johnson's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, JNJ currently prints 24.76% for ROE, while the sector average sits near 29.33%. That is roughly 15.6% below the sector mean. Large gaps often invite a closer look at Johnson & Johnson's growth, margins, and balance sheet.
Return on Equity shows how effectively Johnson & Johnson converts resources into returns. At 24.76%, JNJ may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting JNJ's ROE (24.76%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Johnson & Johnson's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
